By Dave Sebastian
Thermo Fisher Scientific Inc. said it has opened a biologics manufacturing site in Lengnau, Switzerland, as part of its partnership with CSL Ltd.
The company on Friday said it would initially support the manufacturing of CSL's Idelvion drug for patients with hemophilia B after the construction for the 1.5 million-square-foot facility is completed in 2022. It would then serve more biopharma customers through the site.
Thermo Fisher said it would add about 200 employees in connection with the site.
The company's biologics manufacturing network currently includes Princeton, N.J.; St. Louis, Mo.; Groningen, Netherlands; Brisbane, Australia; and Hangzhou, China.
Write to Dave Sebastian at firstname.lastname@example.org
(END) Dow Jones Newswires
October 01, 2021 06:41 ET (10:41 GMT)Copyright (c) 2021 Dow Jones & Company, Inc.